Asco-GU – Clear blue water between Keytruda and kidney cancer rivals
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Sutro bucks the folate trend
Competing folate receptor-targeting projects have recorded one failure after another, but Sutro scores a phase I win.
Anti-amyloid approaches come back from the dead
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.
Go or no go? Big decisions loom for Bristol and Sanofi
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
Semorinemab failure tempers tau hopes
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
